- Home
- JUNS vs CALC Comparison
JUNS vs CALC Comparison
Compare JUNS & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JUNS
- CALC
- Stock Information
- Founded
- JUNS 2015
- CALC 2011
- Country
- JUNS United States
- CALC United States
- Employees
- JUNS N/A
- CALC N/A
- Industry
- JUNS
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- JUNS
- CALC Health Care
- Exchange
- JUNS NYSE
- CALC Nasdaq
- Market Cap
- JUNS 20.5M
- CALC 22.9M
- IPO Year
- JUNS 2024
- CALC N/A
- Fundamental
- Price
- JUNS $2.37
- CALC $2.13
- Analyst Decision
- JUNS
- CALC Strong Buy
- Analyst Count
- JUNS 0
- CALC 2
- Target Price
- JUNS N/A
- CALC $14.50
- AVG Volume (30 Days)
- JUNS 726.6K
- CALC 47.4K
- Earning Date
- JUNS 08-11-2025
- CALC 08-11-2025
- Dividend Yield
- JUNS N/A
- CALC N/A
- EPS Growth
- JUNS N/A
- CALC N/A
- EPS
- JUNS N/A
- CALC N/A
- Revenue
- JUNS N/A
- CALC N/A
- Revenue This Year
- JUNS N/A
- CALC N/A
- Revenue Next Year
- JUNS N/A
- CALC N/A
- P/E Ratio
- JUNS N/A
- CALC N/A
- Revenue Growth
- JUNS N/A
- CALC N/A
- 52 Week Low
- JUNS $0.51
- CALC $1.42
- 52 Week High
- JUNS $19.51
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- JUNS N/A
- CALC 48.14
- Support Level
- JUNS N/A
- CALC $1.59
- Resistance Level
- JUNS N/A
- CALC $1.69
- Average True Range (ATR)
- JUNS 0.00
- CALC 0.15
- MACD
- JUNS 0.00
- CALC 0.01
- Stochastic Oscillator
- JUNS 0.00
- CALC 46.51
About JUNS JUPITER NEUROSCIENCES INC
Jupiter Neurosciences Inc is a clinical-stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a resveratrol platform product that targets the treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to the majority of central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.